当前位置: X-MOL 学术Pharmaceutics › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Therapeutic Approaches for Metastases from Colorectal Cancer and Pancreatic Ductal Carcinoma
Pharmaceutics ( IF 5.4 ) Pub Date : 2021-01-14 , DOI: 10.3390/pharmaceutics13010103
Adriana G. Quiroz-Reyes , Jose F. Islas , Paulina Delgado-Gonzalez , Hector Franco-Villarreal , Elsa N. Garza-Treviño

Metastasis is the process of dissemination of a tumor, whereby cells from the primary site dislodge and find their way to other tissues where secondary tumors establish. Metastasis is the primary cause of death related to cancer. This process warrants changes in original tumoral cells and their microenvironment to establish a metastatic niche. Traditionally, cancer therapy has focused on metastasis prevention by systematic treatments or direct surgical re-sectioning. However, metastasis can still occur. More recently, new therapies direct their attention to targeting cancer stem cells. As they propose, these cells could be the orchestrators of the metastatic niche. In this review, we describe conventional and novel developments in cancer therapeutics for liver and lung metastasis. We further discuss the resistance mechanisms of targeted therapy, the advantages, and disadvantages of diverse treatment approaches, and future novel strategies to enhance cancer prognosis.

中文翻译:

结直肠癌和胰腺导管癌转移的治疗方法

转移是肿瘤扩散的过程,由此来自原发部位的细胞移位并找到通往继发性肿瘤形成的其他组织的途径。转移是与癌症相关的主要死亡原因。这个过程保证了原始肿瘤细胞及其微环境的变化,从而建立了转移性利基。传统上,癌症治疗的重点是通过系统治疗或直接手术切除来预防转移。但是,转移仍然可能发生。最近,新疗法将其注意力转移到靶向癌症干细胞上。正如他们提出的,这些细胞可能是转移性利基的协调者。在这篇综述中,我们描述了肝和肺转移癌治疗中的常规和新型进展。我们将进一步讨论靶向治疗的耐药机制,
更新日期:2021-01-14
down
wechat
bug